Enliven Therapeutics
ELVN • NASDAQ
Enliven Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Richard A. Fair, with a market cap of $2.3B.
CEORichard A. Fair
Next Earnings
Upcoming earnings announcement for Enliven Therapeutics
Date
Wednesday, May 13, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.42
Revenue Estimate
$10.0K
Earnings History
Past 12 earnings reports for Enliven Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 3, 2026 | Q4 2025 | -$0.48Est: -$0.45 | -6.7% | -Est: $10.0K | -100.0% | — |
| Nov 12, 2025 | Q3 2025 | -$0.32Est: -$0.45 | +28.9% | - | — |  10-Q |
| Aug 13, 2025 | Q2 2025 | -$0.49Est: -$0.46 | -6.5% | - | — | 10-Q |
| May 14, 2025 | Q1 2025 | -$0.57Est: -$0.56 | -1.8% | - | — | 10-Q |
| Mar 13, 2025 | Q4 2024 | -$0.46Est: -$0.52 | +11.5% | - | — | 10-K |
| Nov 13, 2024 | Q3 2024 | -$0.48Est: -$0.50 | +4.0% | - | — | 10-Q |
| Aug 13, 2024 | Q2 2024 | -$0.41Est: -$0.55 | +25.5% | - | — | 10-Q |
| May 14, 2024 | Q1 2024 | -$0.54Est: -$0.57 | +5.3% | - | — | 10-Q |
| Mar 14, 2024 | Q4 2023 | -$0.47Est: -$0.54 | +13.0% | -Est: - | — | 10-K |
| Nov 9, 2023 | Q3 2023 | -$0.51Est: -$0.47 | -8.5% | - | — | — |
| Aug 10, 2023 | Q2 2023 | -$0.41Est: -$0.36 | -13.9% | - | — | 10-Q |
| May 11, 2023 | Q1 2023 | -$0.80Est: -$0.63 | -27.0% | - | — | 10-Q |